## Introduction
In the high-stakes world of modern medicine, a critical tension exists between the uniform safety standards set by the federal government and the rights of individuals to seek justice under state law when harmed. When an FDA-approved medical device or drug causes injury, it raises a fundamental legal question: can the manufacturer be sued, or does federal approval provide complete immunity? This article addresses this knowledge gap by exploring the intricate legal concept of a **parallel claim**, a crucial pathway that harmonizes federal authority with state-level justice. Across the following sections, you will learn the core legal principles that govern this balance. The "Principles and Mechanisms" section will dissect federal preemption and the two critical legal "gates" a claim must pass to survive. The "Applications and Interdisciplinary Connections" section will then illustrate how this doctrine applies to real-world scenarios involving medical devices, drugs, and even software, revealing how justice can be pursued by enforcing existing rules rather than challenging them.

## Principles and Mechanisms

Imagine a grand balancing act. On one side, you have the immense power of a national government, striving to create uniform, predictable rules for all. On the other, you have the deeply rooted tradition of individual states acting as guardians of their citizens' health and safety. Nowhere is this tension more palpable, or the stakes higher, than in the world of modern medicine. Life-saving medical devices and drugs are marvels of science, but they are not without risk. When something goes wrong and a patient is injured, a fundamental question arises: who gets to set the rules for justice? The answer, a complex and beautiful dance between federal authority and state law, lies at the heart of a legal concept known as a **parallel claim**.

To understand this concept, we must begin with the ultimate rule of the American legal system.

### The Supremacy Clause: The Ultimate Rule of the Road

Buried in Article VI of the United States Constitution is a short but powerful sentence called the **Supremacy Clause**. It declares that federal law is the "supreme Law of the Land." This means that when a valid federal law and a state law clash, the federal law wins. The state law is "preempted"—a legal term for being rendered void.

This preemption isn't a monolithic force; it comes in several flavors. Sometimes, Congress is explicit, writing directly into a statute that it intends to displace state law. This is called **express preemption**. Other times, the preemption is implied. This can happen when a federal regulatory scheme is so comprehensive that it leaves no room for state involvement—a concept called **field preemption**. More commonly, it occurs when it's simply impossible to obey both federal and state law, or when a state law stands as an obstacle to achieving Congress's goals. This is known as **conflict preemption**. [@problem_id:4483343]

The world of medical products provides a perfect laboratory for seeing these principles in action. The Food and Drug Administration (FDA) serves as the nation's chief regulator, creating a dense thicket of federal rules. This sets the stage for a dramatic conflict.

### The Preemption Gauntlet: A Tale of Two Gates

Imagine a patient injured by a sophisticated, FDA-approved cardiac stent. They decide to sue the manufacturer in state court, arguing the stent was negligently designed. The manufacturer’s lawyers would likely make a powerful argument: "Our stent's design received Premarket Approval (PMA) from the FDA after a rigorous, science-based review. This approval represents a specific federal requirement. Your lawsuit, which claims our approved design is unsafe, is attempting to impose a *state* requirement that is 'different from, or in addition to' the federal one. Therefore, your claim is expressly preempted by federal law."

This argument is based on a specific provision in the Medical Device Amendments (MDA) to the Food, Drug, and Cosmetic Act (21 U.S.C. § 360k(a)), which contains that exact "different from, or in addition to" language. At first glance, this seems like a brick wall. If the FDA has approved a product, is there any recourse for those it harms?

Here is where the genius of the legal system reveals a hidden path. The path is not about creating a new rule but about enforcing the existing one. To walk this path, a patient's claim must pass through two critical gates of preemption.

#### Gate 1: Avoiding the "Different or Additional" Trap (Express Preemption)

The first gate is the express preemption clause of the MDA. The key to unlocking it is to understand that it preempts claims that *challenge* the FDA's judgment, but not claims that *enforce* it.

A state lawsuit that claims an FDA-approved device design is defective is, in essence, asking a state court jury to second-guess the FDA's scientific determination. This would be creating a new, "different" safety standard, and it is preempted. Likewise, a claim that a manufacturer should have included stronger warnings than the ones the FDA specifically approved is also preempted. [@problem_id:4496721]

But what if the manufacturer didn't follow the FDA's rules? What if the PMA approval specifies the device must be built with a particular titanium alloy, but the company secretly used a cheaper, weaker metal to cut costs? Or what if the FDA required a specific sterilization process to ensure the device was free of contaminants, but the company got sloppy and skipped a step on one production batch? [@problem_id:4483274]

In these cases, a lawsuit isn't imposing a *new* requirement. It's demanding adherence to the *existing* federal requirement. The state-law duty to produce a non-defective product runs in perfect parallel with the federal duty to follow the PMA specifications. This is the essence of a **parallel claim**. The lawsuit survives the first gate because it doesn't seek to establish a requirement "different from, or in addition to" federal law; it seeks a remedy for a violation of a duty that is **genuinely equivalent** to federal law. [@problem_id:4483423]

#### Gate 2: Not Doing the FDA's Job (Implied Preemption)

Passing the first gate is not enough. There is a second, more subtle trap: implied preemption. Federal law states that only the U.S. government can bring actions to enforce the Food, Drug, and Cosmetic Act (21 U.S.C. § 337(a)). This means a private citizen cannot simply go to court and sue a company for "violating the FDCA." Such a claim is said to be impliedly preempted because it would interfere with the FDA's exclusive enforcement authority.

This principle, clarified in the landmark Supreme Court case *Buckman Co. v. Plaintiffs’ Legal Committee*, means that any state-law claim that exists "solely by virtue of" federal law is barred. [@problem_id:4483295] For example, a manufacturer has a duty to report certain adverse events to the FDA. This is a duty owed to the regulator. A patient cannot sue a manufacturer simply for failing to file these reports. Such a claim would have no basis in traditional state law and would exist only because of the federal reporting regulation. It is, in effect, a private citizen trying to do the FDA's job. This is not allowed. [@problem_id:4483358]

### Threading the Needle: The Anatomy of a Parallel Claim

So, how does a claim pass through both gates? The successful parallel claim is a work of legal art. It must be rooted in a traditional state-law duty (like negligence or product liability) that exists independently of the federal rules. But it uses the violation of a specific federal requirement as the *proof* that the state-law duty was breached.

Let's construct one. Imagine a company's FDA-approved manufacturing plan for a spinal implant specifies that a component must be heated to 500 degrees Celsius. State law has always recognized a manufacturer's duty to exercise reasonable care in making its products. Now, suppose the company, to speed up production, only heats the component to 400 degrees, resulting in a brittle implant that later fractures inside a patient. [@problem_id:4496728]

The patient's claim would be for negligence under state law.
- Does it pass Gate 1? Yes. It does not challenge the FDA's approved 500-degree specification. In fact, it embraces it. It doesn't impose a "different or additional" requirement; it enforces an equivalent one.
- Does it pass Gate 2? Yes. The claim is not "solely" for violating an FDA rule. It's for breaching the traditional state-law duty of reasonable care. The fact that the company violated the FDA's specific rule is powerful—even conclusive—*evidence* that it breached its state-law duty.

The claim survives because the federal requirement and the state duty are parallel. The lawsuit doesn't create a new legal duty; it provides a state-law remedy for the breach of a duty that federal law has already defined. To win, the patient would need to prove it, producing evidence like the FDA's approval documents setting the standard, the company's own batch records showing the deviation, and expert testimony linking that deviation to the injury. [@problem_id:4483274] [@problem_id:4483309]

### The Unsettled Frontier: When Judges Disagree

This elegant structure brings a beautiful logic and unity to a complex field, but it would be a mistake to think it is always simple. The law is a living thing, interpreted by human judges, and sometimes they disagree. These disagreements between the U.S. Courts of Appeals for different regions are called **circuit splits**.

One of the most prominent circuit splits in this area involves the very "failure to report adverse events" claims we discussed earlier. While a claim that exists *solely* to punish a failure to report to the FDA is preempted under *Buckman*, some courts have viewed the issue differently. Courts in some circuits (like the Ninth and Seventh) have reasoned that a manufacturer has a general state-law duty to warn doctors and patients of risks. They argue that failing to report adverse events to the FDA—the primary channel for monitoring and communicating new risks—can be seen as a breach of that broader state-law duty to warn. Other circuits (like the Eighth and Fifth) disagree, viewing any claim based on a failure to report to the FDA as a prohibited attempt to privately enforce the FDCA. [@problem_id:4483288]

This split shows that the line between a preempted claim and a valid parallel claim can be razor-thin, turning on subtle distinctions in legal reasoning. It reminds us that the balancing act between federal power and state protection is not static. It is a dynamic and ongoing conversation, a testament to the law's continuing effort to provide justice in an ever-evolving technological world.